Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Existing shareholders face potential dilution if employees exercise the newly granted options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) granted six newly hired non-executive employees stock options on October 1, 2026, as inducements to join the company.
The options cover 157,500 common shares at an exercise price of $0.8165 per share, matching the closing share price on the grant date. They vest over four years: 25% on the first anniversary of each employee’s start date, followed by equal monthly installments, subject to continuous service. The options have a 10-year term and were granted under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 157,500 common shares at $0.8165 per share could dilute existing holders if exercised.
Key Figures
- Options granted
- 157,500 shares
- Aggregate options for six newly hired non-executive employees
- Exercise price
- $0.8165 per share
- Equal to the closing price on the grant date
- Vesting period
- 4 years
- Subject to continuous service
- Initial vesting
- 25%
- Vests on the first anniversary of the employee’s start date
- Option term
- 10 years
- Term of each option
Historical Context
-
Six new hires received options under the 2026 Inducement Plan at a $0.8799 exercise price.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
The options have a per share exercise price of
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many employee stock options did Invivyd grant and at what exercise price?
Invivyd granted options covering 157,500 common shares at an exercise price of $0.8165 per share. The October 1, 2026 grants went to six newly hired non-executive employees as employment inducements. The exercise price matched the closing price of Invivyd’s common stock on the grant date.